Emerging investigations have shown that exosomal levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 in neuronal‐derived exosomes from plasma could predict the progress of AD up to 10 years before clinical onset, showing the biomarker potential of EV‐based assays. Here, MAPT is linked to Alzheimer disease.